Preclinical Drug Development

• reduce late stage attrition of drug candidates through early elimination of non-druggable compounds with adverse ADMET characterisitcs
• rescue compounds that have reported preclinical toxicity by determining the relevance to man
• accelerate preclinical development by developing new more informative preclinical models

Hazard and Risk Assessment of Chemicals

• providing mechanism based human risk assessment for chemicals
• investigating the mechanisms underlying toxic properties of chemicals and drugs
• determining the relevance to man of results from safety studies in animals
• preparing the documentation required for product support and accreditation (eg REACH)

By providing expert services and developing innovative technologies, CXR Biosciences can:

• ..reduce late stage product attrition
• ..accelerate drug development
• ..rescue chemicals and drugs that may otherwise be abandoned
• ..transform the human risk assessment of drugs and chemicals
• ..improve the clinical predictability of drug discovery ADMET screens